Alexandre Barcia Godoi

Mr. Alexandre Barcia Godoi

School of Medical Sciences (FCM-UNICAMP), University of Campinas-UNICAMP, Campinas, São Paulo, Brazil
+1
orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 September 2020 in Metabolites
Verified
Journal Article
Open access
PDF file
ADAmanda Donatti
Amanda Donatti
Amanda Morato do CantoAmanda Morato do Canto
Amanda Morato do Canto
Alexandre Barcia GodoiAlexandre Barcia Godoi
Alexandre Barcia Godoi
DRDouglas Cescon da Rosa
Douglas Cescon da Rosa
Iscia Lopes-CendesIscia Lopes-Cendes
Iscia Lopes-Cendes
There are, still, limitations to predicting the occurrence and prognosis of neurological disorders. Biomarkers are molecules that can change in different conditions, a feature that makes them potential tools to improve the diagnosis of disease, establish a prognosis, and monitor treatments. Metabolites can be used as biomarkers, and are small molecules derived from the metabolic process found in different biological media, such as tissue samples, cells, or biofluids. They can be identified using various strategies, targeted or untargeted experiments, and by different techniques, such as high-performance liquid chromatography, mass spectrometry, or nuclear magnetic resonance. In this review, we aim to discuss the current knowledge about metabolites as biomarkers for neurological disorders. We will present recent developments that show the need and the feasibility of identifying such biomarkers in different neurological disorders, as well as discuss relevant research findings in the field of metabolomics that are helping to unravel the mechanisms underlying neurological disorders. Although several relevant results have been reported in metabolomic studies in patients with neurological diseases, there is still a long way to go for the clinical use of metabolites as potential biomarkers in these disorders, and more research in the field is needed.

7 January 2021 in Frontiers in Molecular Neuroscience
Verified
Journal Article
Open access
ACAmanda M. Do Canto
Amanda M. Do Canto
ADAmanda Donatti
Amanda Donatti
JGJaqueline C. Geraldis
Jaqueline C. Geraldis
Alexandre Barcia GodoiAlexandre Barcia Godoi
Alexandre Barcia Godoi
DRDouglas C. da Rosa
Douglas C. da Rosa
Iscia Lopes-CendesIscia Lopes-Cendes
Iscia Lopes-Cendes
Epilepsies are chronic neurological diseases that affect approximately 2% of the world population. In addition to being one of the most frequent neurological disorders, treatment for patients with epilepsy remains a challenge, because a proportion of patients do not respond to the antiseizure medications that are currently available. This results in a severe economic and social burden for patients, families, and the healthcare system. A characteristic common to all forms of epilepsy is the occurrence of epileptic seizures that are caused by abnormal neuronal discharges, leading to a clinical manifestation that is dependent on the affected brain region. It is generally accepted that an imbalance between neuronal excitation and inhibition generates the synchronic electrical activity leading to seizures. However, it is still unclear how a normal neural circuit becomes susceptible to the generation of seizures or how epileptogenesis is induced. Herein, we review the results of recent proteomic studies applied to investigate the underlying mechanisms leading to epilepsies and how these findings may impact research and treatment for these disorders.

1 August 2021 in Seizure: European Journal of Epilepsy
Verified
Journal Article
Closed access
EBEstela M. Bruxel
Estela M. Bruxel
DBDanielle C.F. Bruno
Danielle C.F. Bruno
ACAmanda M. Do Canto
Amanda M. Do Canto
JGJaqueline C. Geraldis
Jaqueline C. Geraldis
Alexandre Barcia GodoiAlexandre Barcia Godoi
Alexandre Barcia Godoi
Iscia Lopes-CendesIscia Lopes-Cendes
Iscia Lopes-Cendes

10 October 2020 in Hippocampus
Verified
Journal Article
Closed access
PDF file
Amanda Morato do CantoAmanda Morato do Canto
Amanda Morato do Canto
AMAlexandre H. B. Matos
Alexandre H. B. Matos
Alexandre Barcia GodoiAlexandre Barcia Godoi
Alexandre Barcia Godoi
AVAndré S. Vieira
André S. Vieira
BABeatriz B. Aoyama
Beatriz B. Aoyama
Iscia Lopes-CendesIscia Lopes-Cendes
Iscia Lopes-Cendes

9 February 2024 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Alexandre Barcia GodoiAlexandre Barcia Godoi
Alexandre Barcia Godoi
NANatalicia De Jesus Antunes
Natalicia De Jesus Antunes
KCKelly Francisco Cunha
Kelly Francisco Cunha
AMAline Franco Martins
Aline Franco Martins
MHMarilyn Ann Huestis
Marilyn Ann Huestis
José Luiz CostaJosé Luiz Costa
José Luiz Costa
New Psychoactive Substances (NPSs) are defined as a group of substances produced from molecular modifications of traditional drugs. These molecules represent a public health problem since information about their metabolites and toxicity is poorly understood. N-ethyl pentedrone (NEP) is an NPS that was identified in the illicit market for the first time in the mid-2010s, with four intoxication cases later described in the literature. This study aims to evaluate the metabolic stability of NEP as well as to identify its metabolites using three liver microsomes models. To investigate metabolic stability, NEP was incubated with rat (RLM), mouse (MLM) and human (HLM) liver microsomes and its concentration over time evaluated by liquid chromatography–mass spectrometry. For metabolite identification, the same procedure was employed, but the samples were analyzed by liquid chromatography–high resolution mass spectrometry. Different metabolism profiles were observed depending on the model employed and kinetic parameters were determined. The in vitro NEP elimination half-lives (t1/2) were 12.1, 187 and 770 min for the rat, mouse and human models, respectively. Additionally, in vitro intrinsic clearances (Cl int, in vitro) were 229 for rat, 14.8 for mouse, and 3.6 μL/min/mg in the human model, and in vivo intrinsic clearances (Cl int, in vivo) 128, 58.3, and 3.7 mL/min/kg, respectively. The HLM model had the lowest rate of metabolism when compared to RLM and MLM. Also, twelve NEP metabolites were identified from all models, but at different rates of production.

17 May 2022 in Metabolites
Verified
Journal Article
Open access
PDF file
Alexandre Barcia GodoiAlexandre Barcia Godoi
Alexandre Barcia Godoi
Amanda Morato do CantoAmanda Morato do Canto
Amanda Morato do Canto
ADAmanda Donatti
Amanda Donatti
DRDouglas Cescon da Rosa
Douglas Cescon da Rosa
DBDanielle Bruno
Danielle Bruno
Iscia Lopes-CendesIscia Lopes-Cendes
Iscia Lopes-Cendes
A major challenge in the clinical management of patients with mesial temporal lobe epilepsy (MTLE) is identifying those who do not respond to antiseizure medication (ASM), allowing for the timely pursuit of alternative treatments such as epilepsy surgery. Here, we investigated changes in plasma metabolites as biomarkers of disease in patients with MTLE. Furthermore, we used the metabolomics data to gain insights into the mechanisms underlying MTLE and response to ASM. We performed an untargeted metabolomic method using magnetic resonance spectroscopy and multi- and univariate statistical analyses to compare data obtained from plasma samples of 28 patients with MTLE compared to 28 controls. The patients were further divided according to response to ASM for a supplementary and preliminary comparison: 20 patients were refractory to treatment, and eight were responsive to ASM. We only included patients using carbamazepine in combination with clobazam. We analyzed the group of patients and controls and found that the profiles of glucose (p = 0.01), saturated lipids (p = 0.0002), isoleucine (p = 0.0001), β-hydroxybutyrate (p = 0.0003), and proline (p = 0.02) were different in patients compared to controls (p < 0.05). In addition, we found some suggestive metabolites (without enough predictability) by multivariate analysis (VIP scores > 2), such as lipoproteins, lactate, glucose, unsaturated lipids, isoleucine, and proline, that might be relevant to the process of pharmacoresistance in the comparison between patients with refractory and responsive MTLE. The identified metabolites for the comparison between MTLE patients and controls were linked to different biological pathways related to cell-energy metabolism and pathways related to inflammatory processes and the modulation of neurotransmitter release and activity in MTLE. In conclusion, in addition to insights into the mechanisms underlying MTLE, our results suggest that plasma metabolites may be used as disease biomarkers. These findings warrant further studies exploring the clinical use of metabolites to assist in decision-making when treating patients with MTLE.